Phase i dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 51-57

  Fields, Emma C ^a   Damek, Denise ^a   Gaspar, Laurie E ^a   Liu, Arthur K ^a   Kavanagh, Brian D ^a   Waziri, Allen ^a   Lillehei, Kevin ^a   Chen, Changhu ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Recurrent malignant glioma; SRS; Stereotactic radiosurgery; Vandetanib

Indexed keywords

ADVERSE EVENTS; ANAPLASTIC ASTROCYTOMA; ANTI-COAGULATION; COMMON TERMINOLOGY CRITERIA; DISEASE PROGRESSION; DOSE ESCALATION; DOSE LIMITING TOXICITY; HEMATOLOGIC TOXICITY; MALIGNANT GLIOMA; MAXIMUM TOLERATED DOSE; NONHEMATOLOGIC TOXICITY; PHASE I; RADIOSURGERY; RECURRENT TUMORS; SRS; STEREOTACTIC RADIOSURGERY; VANDETANIB;

RADIOTHERAPY; TOXICITY; TUMORS;

INTERACTIVE COMPUTER SYSTEMS;

CARBOPLATIN; DEXAMETHASONE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; TEMOZOLOMIDE; VANDETANIB; VINCRISTINE; WARFARIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TOXICITY; BRADYCARDIA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLEX PARTIAL SEIZURE; CONFUSION; CORTICOSTEROID THERAPY; CRANIOTOMY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EMBOLISM PREVENTION; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HEMATOTHORAX; HEMATURIA; HUMAN; HYPERTENSION; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MENTAL HEALTH; NAUSEA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; SEIZURE; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR VOLUME; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CARBOPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; GLUCOCORTICOIDS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; PROSPECTIVE STUDIES; QUINAZOLINES; RADIOSURGERY; RADIOTHERAPY DOSAGE; TUMOR BURDEN; VINCRISTINE; YOUNG ADULT;

EID: 83955164336     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.09.008     Document Type: Article

References (31)

1. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
2. R.C. Rostomily, A.M. Spence, and D. Duong Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery Neurosurgery 35 1994 378 388
3. C.F. Hess, J.C. Schaaf, and R.D. Kortmann Malignant glioma: Patterns of failure following individually tailored limited volume irradiation Radiother Oncol 30 1994 146 149
4. D.C. Shrieve, E. Alexander III, and P.Y. Wen Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme Neurosurgery 36 1995 275 282
5. R.S. Hudes, B.W. Corn, and M. Werner-Wasik A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma Int J Radiat Oncol Biol Phys 43 1999 293 298
6. K.H. Cho, W.A. Hall, and B.J. Gerbi Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas Int J Radiat Oncol Biol Phys 45 1999 1133 1141
7. S.F. Shepherd, R.W. Laing, and V.P. Cosgrove Hypofractionated stereotactic radiotherapy in the management of recurrent glioma Int J Radiat Oncol Biol Phys 37 1997 393 398
8. J. Glass, C.L. Silverman, R. Axelrod, and B.W. Corn Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma Am J Clin Oncol 20 1997 226 229
9. G. Lederman, M. Wronski, and E. Arbit Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel Am J Clin Oncol 23 2000 155 159
10. E.T. Wong, K.R. Hess, and M.J. Gleason Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 1999 2572 2578
11. J.R. Perry, K. Bélanger, and W.P. Mason Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 2010 2051 2057
12. P.Y. Wen Therapy for recurrent high-grade gliomas: Does continuous dose-intense temozolomide have a role? J Clin Oncol 28 2010 1977 1979
13. V. Damiano, D. Melisi, and C. Bianco Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma Clin Cancer Res 11 2005 5639 5644
14. S.R. Wedge, D.J. Ogilvie, and M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
15. F. Carlomagno, D. Vitagliano, and T. Guida ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 2002 7284 7290
16. M. Sandstrom, M. Johansson, and P. Bergstrom Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model J Neurooncol 88 2008 1 9
17. S.N. Holden, S.G. Eckhardt, and R. Basser Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann Oncol 16 2005 1391 1397
18. K.D. Miller, J.M. Trigo, and C. Wheeler A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer Clin Cancer Res 11 2005 3369 3376
19. J.V. Heymach, L. Paz-Ares, and F. De Braud Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 26 2008 5407 5415
20. R.S. Herbst, Y. Sun, and W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial Lancet Oncol 2010 Jun 4 [Epub ahead of print]
21. J. Drappatz, A.D. Norden, and E.T. Wong Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma Int J Radiat Oncol Biol Phys 2010 Feb 3 [Epub ahead of print]
22. A.L. Schwer, D.M. Damek, and B.D. Kavanagh A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas Int J Radiat Oncol Biol Phys 70 2008 993 1001
23. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) Available at: http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcaev3.pdf Accessed May 23, 2010
24. L.C. Marras, W.H. Geerts, and J.R. Perry The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review Cancer 89 2000 640 646
25. Stereotactic radiosurgery definition Int J Radiat Oncol Biol Phys 67 2007 1280
26. D. Macdonald, T. Cascino, and S.J. Schold Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280
27. J.J. Vrendenburgh, A. Desjardins, and J.E. Herndon II Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
28. T.N. Kriesl, L. Kim, and K. Moore Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
29. T. Batchelor, A. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95
30. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
31. S.E. Fogh, D.W. Andrews, and J. Glass Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas J Clin Oncol 28 2010 3048 3053